Oric Pharmaceuticals Inc

Stock Chart, Company Information, and Scan Results

$14.53(as of Oct 6, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Oric Pharmaceuticals Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$14.53
Ticker SymbolORIC
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees128
CountyUSA
Market Cap$1,123.2M
EBIDTA-148.5M
10-Day Moving Average11.51
P/E Ratio-8.20
20-Day Moving Average11.13
Forward P/E Ratio0.00
50-Day Moving Average10.48
Earnings per Share-1.89
200-Day Moving Average8.72
Profit Margin-Infinity%
RSI76.33
Shares Outstanding97.1M
ATR0.77
52-Week High14.67
Volume3,722,956
52-Week Low3.90
Most Recent Support Level11.13
Book Value324.0M
Most Recent Resistance Level12.13
P/B Ratio3.47
Upper Keltner12.86
P/S Ratio1,056.10
Lower Keltner9.40
Debt-to-Equity Ratio12.86
Next Earnings Date11/10/2025
Cash Surplus57.8M
Next Ex-Dividend DateUnknown

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Oric Pharmaceuticals Inc In Our Stock Scanner

As of Oct 07, 2025
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.